Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Cassava Sciences Inc (FLNA) Price & Performance

Crispr Therapeutics AGTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Cassava Sciences Inc — how do they compare? Crispr Therapeutics AG trades at $54.02 (market cap $5.23B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Crispr Therapeutics AG is far larger — about 109.5× Cassava Sciences Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

CRSPFLNA
Market Cap
$5.23B$47.75M
Sector
HealthHealth
52-Week High
$76.78$4.64
52-Week Low
$44.34$0.87
Enterprise Value
$3.65B-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.

Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA